Immunology Research Center, TabrizUniversity of Medical Sciences, Tabriz, Iran.
Department of Cancer and Inflammation Research, Institute for Molecular Medicine, University of Southern Denmark, Odense, Denmark.
J Cell Physiol. 2019 Dec;234(12):22581-22592. doi: 10.1002/jcp.28823. Epub 2019 May 20.
One of the major obstacles in the treatment of cancer is resistance to standard chemotherapeutic drugs. According to the numerous reports, miR-200c is involved in many cancers, especially gastric cancer, and also miR-200c has been known as an effective factor in the elimination of chemotherapy resistance. The purpose of this study was to explore the potential function and mechanism of miR-200c and cisplatin in the inhibition of migration and induction of apoptosis in gastric cancer cells. In this study, first, miR-200c mimics and LNA-anti-miR-200c were transfected into KATOIII cells. Moreover, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay results revealed that increased miR-200c expression and cisplatin can more inhibited the proliferation of KATOIII cells. MiR-200c overexpression inhibited the movement of KATOIII cells in wound healing assay. Subsequently, miR-200c/cisplatin could suppress colony formation in KATOIII cells. To identify a potential miR-200c target, we investigated the effect of miR-200c modulation on RhoE, PTEN, VEGFR, and MMP9 expression levels. Increased miR-200c expression caused a reduction in VEGFR and MMP9 mRNA and protein, suggesting that VEGFR and MMP9 are targets of miR-200c. In addition, reverse-transcription polymerase chain reaction assays showed that RhoE is target gene of miR-200c and LNA-anti-miR-200c suppressed the expression of PTEN. Flow cytometry and 4',6-diamidino-2-phenylindole staining analysis indicated that miR-200c increased the cisplatin-induced apoptosis which may be associated with suppression of RhoE expression in KATOIII cells, also cell-cycle analysis showed the arrest of cell-cycle progression at the G2 phase. These data demonstrated that miR-200c functioned as a suppressor gene in KATOIII cells. Also, miR-200c can be a potential therapeutic approach to overcome chemoresistance during cisplatin chemotherapy.
癌症治疗中的一个主要障碍是对标准化疗药物的耐药性。根据众多报道,miR-200c 参与多种癌症,特别是胃癌,并且 miR-200c 已被证明是消除化疗耐药性的有效因素。本研究旨在探讨 miR-200c 和顺铂抑制胃癌细胞迁移和诱导凋亡的潜在功能和机制。在这项研究中,首先将 miR-200c 模拟物和 LNA-anti-miR-200c 转染到 KATOIII 细胞中。此外,3-(4,5-二甲基噻唑-2-基)-2,5-二苯基四氮唑溴盐测定结果表明,miR-200c 表达增加和顺铂可更抑制 KATOIII 细胞的增殖。miR-200c 过表达抑制 KATOIII 细胞在划痕愈合试验中的运动。随后,miR-200c/顺铂可抑制 KATOIII 细胞的集落形成。为了鉴定潜在的 miR-200c 靶标,我们研究了 miR-200c 调节对 RhoE、PTEN、VEGFR 和 MMP9 表达水平的影响。miR-200c 表达增加导致 VEGFR 和 MMP9 mRNA 和蛋白减少,表明 VEGFR 和 MMP9 是 miR-200c 的靶标。此外,逆转录聚合酶链反应测定显示 RhoE 是 miR-200c 的靶基因,LNA-anti-miR-200c 抑制了 PTEN 的表达。流式细胞术和 4',6-二脒基-2-苯基吲哚染色分析表明,miR-200c 增加了顺铂诱导的凋亡,这可能与 KATOIII 细胞中 RhoE 表达的抑制有关,细胞周期分析也显示细胞周期在 G2 期停滞。这些数据表明 miR-200c 在 KATOIII 细胞中作为一种抑制基因发挥作用。此外,miR-200c 可能是克服顺铂化疗中化疗耐药性的潜在治疗方法。